


WHAT IS CLAIMED IS:

1. A compound of structural Formula I:



or a pharmaceutically acceptable salt thereof, wherein

A is heteroaryl or heteroaryl fused to a saturated or unsaturated 5- or 6-membered ring containing 0-3 heteroatoms independently selected from O, S and N(R^h)_q, wherein each heteroaryl, 5-membered ring and 6-membered ring is unsubstituted or substituted with one to five substituents selected from R^a;

B is heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents selected from R^b;

R¹ is selected from the group consisting of:

- (1) hydrogen,
- (2) -SO₃H,
- (3) -SO₂NH₂,
- (4) -SO₂NReC₁₋₆alkyl,
- (5) -SO₂NReC(O)C₁₋₆alkyl,
- (6) -SO₂NReC₂₋₆alkenyl,
- (7) -SO₂NReC₃₋₆cycloalkyl,
- (8) -SO₂NReC(O)C₃₋₆cycloalkyl,
- (9) -SO₂NReC₂₋₆cycloheteroalkyl,
- (10) -SO₂NReC(O)C₂₋₆cycloheteroalkyl,
- (11) -SO₂NRe-aryl,
- (12) -SO₂NRe-heteroaryl,
- (13) -SO₂C₁₋₆alkyl,
- (14) -SO₂C₁₋₆alkenyl,
- (15) -SO₂C₃₋₆cycloalkyl,

- (16) $-\text{SO}_2\text{C}_{2-6}\text{cycloheteroalkyl}$,
 (17) $-\text{SO}_2\text{aryl}$,
 (18) $-\text{SO}_2\text{heteroaryl}$,
 (19) $-\text{S}(\text{O})\text{R}^j$,
 5 (20) $-\text{SR}^j$,
 (21) $-\text{C}(\text{O})\text{NH}_2$,
 (22) $-\text{C}(\text{O})\text{NReR}^j$,
 (23) $-\text{CO}_2\text{H}$,
 (24) $-\text{CO}_2\text{R}^j$,
 10 (25) $-\text{C}(\text{O})\text{R}^j$,
 (26) $-\text{CN}$,
 (27) CF_3 ,
 (28) halogen,
 (29) $-\text{OH}$,
 15 (30) $-\text{OC}_{1-6}\text{alkyl}$,
 (31) $-\text{OC}_{2-6}\text{alkenyl}$,
 (32) $-\text{OC}_{3-6}\text{cycloalkyl}$,
 (33) $-\text{OC}_{2-6}\text{cycloheteroalkyl}$,
 (34) $-\text{O-aryl}$,
 20 (35) $-\text{O-heteroaryl}$,
 (36) $-\text{OC}(\text{O})\text{R}^j$,
 (37) $-\text{OC}(\text{O})\text{NReR}^j$,
 (38) $-\text{OC}(\text{O})\text{N}(\text{R}^j)_2$,
 (39) $-\text{C}_{1-6}\text{alkyl}$,
 25 (40) $-\text{C}_{2-6}\text{alkenyl}$,
 (41) $-\text{C}_{1-6}\text{cycloalkyl}$,
 (42) $-\text{C}_{2-6}\text{cycloheteroalkyl}$,
 (43) aryl,
 (44) heteroaryl,
 30 (45) $-(\text{CH}_2)_n\text{NReC}(\text{O})\text{R}^j$,
 (46) $-(\text{CH}_2)_n\text{NReC}(\text{O})\text{OR}^j$,
 (47) $-(\text{CH}_2)_n\text{NReC}(\text{O})\text{N}(\text{Re})_2$,
 (48) $-(\text{CH}_2)_n\text{NReC}(\text{O})\text{NReR}^j$,
 (49) $-(\text{CH}_2)_n\text{NReC}(\text{O})\text{N}(\text{R}^j)_2$,
 35 (50) $-(\text{CH}_2)_n\text{NReS}(\text{O})_m\text{R}^j$,
 (51) $-(\text{CH}_2)_n\text{NReS}(\text{O})_m\text{N}(\text{Re})_2$,
 (52) $-(\text{CH}_2)_n\text{NReS}(\text{O})_m\text{NReR}^j$,



wherein each CH_2 , alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to four substituents selected from R^d ;

5

R^2 is selected from the group consisting of:

- (1) hydrogen, and
- (2) $-\text{C}_{1-6}\text{alkyl}$;

10 R^3 is selected from the group consisting of:

- (1) a monocyclic, bicyclic or spirocyclic C_{3-12} cycloalkyl ring, and
- (2) a monocyclic, bicyclic or spirocyclic C_{2-12} cycloheteroalkyl ring,

wherein the cycloheteroalkyl contains 1-4 heteroatoms independently selected from $\text{N}(\text{R}^m)_r$, O, and S, wherein each cycloalkyl ring and each cycloheteroalkyl ring may be fused to an aryl or

15 heteroaryl, and wherein each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to eight substituents selected from R^c ;

each R^a is selected from the group consisting of:

- (1) $-\text{C}_{1-6}\text{alkyl}$,
- 20 (2) $-\text{OC}_{1-6}\text{alkyl}$,
- (3) halogen,
- (4) $-\text{OH}$,
- (5) oxo,
- (6) $-\text{CN}$,
- 25 (7) $-\text{C}_{3-6}\text{cycloalkyl}$, and
- (8) $-\text{C}_{2-5}\text{cycloheteroalkyl}$,

wherein each alkyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to six substituents selected from halogen, OH, NH_2 , $\text{NH}(\text{C}_{1-6}\text{alkyl})$ and $\text{N}(\text{C}_{1-6}\text{alkyl})_2$;

30 each R^b is independently selected from the group consisting of:

- (1) $-\text{CF}_3$,
- (2) $-\text{CF}_2\text{CF}_3$,
- (3) $-\text{CHF}_2$,
- (4) $-\text{OCHF}_2$,
- 35 (5) $-\text{OCH}_2\text{CF}_3$,
- (6) $-\text{OCF}_3$,
- (7) CN ,

- (8) halogen,
 (9) -Si(C₁₋₆alkyl)₃,
 (10) -C₁₋₆alkyl-O-R^k,
 (11) -C₁₋₆alkyl,
 5 (12) -C₂₋₆alkenyl,
 (13) -C₂₋₆alkynyl,
 (14) -C₃₋₆cycloalkyl,
 (15) -C₂₋₆cycloheteroalkyl,
 (16) aryl,
 10 (17) heteroaryl,
 (18) -C₁₋₆alkyl-C₃₋₆cycloalkyl,
 (19) -C₁₋₆alkyl-C₂₋₆cycloheteroalkyl,
 (20) -C₁₋₆alkyl-aryl,
 (21) -C₁₋₆alkyl-heteroaryl,
 15 (22) -C₂₋₆alkenyl-C₃₋₆cycloalkyl,
 (23) -C₂₋₆alkenyl-C₂₋₆cycloheteroalkyl,
 (24) -C₂₋₆alkenyl-aryl,
 (25) -C₂₋₆alkenyl-heteroaryl,
 (26) -C₂₋₆alkynyl-C₃₋₆cycloalkyl,
 20 (27) -C₂₋₆alkynyl cycloheteroalkyl,
 (28) -C₂₋₆alkynyl-aryl,
 (29) -C₂₋₆alkynyl-heteroaryl,
 (30) NO₂,
 (31) -OH,
 25 (32) -(CH₂)_p-OC₁₋₆alkyl,
 (33) -(CH₂)_p-OC₂₋₆alkenyl,
 (34) -(CH₂)_p-OC₂₋₆alkynyl,
 (35) -(CH₂)_p-OC₃₋₆cycloalkyl,
 (36) -(CH₂)_p-OC₂₋₆heterocycloalkyl,
 30 (37) -(CH₂)_p-O-aryl,
 (38) -(CH₂)_p-O-heteroaryl,
 (39) -OC₁₋₆alkyl-C₃₋₆cycloalkyl,
 (40) -OC₁₋₆alkyl-C₂₋₆heterocycloalkyl,
 (41) -OC₁₋₆alkyl-aryl,
 35 (42) -OC₁₋₆alkyl-heteroaryl,
 (1) -S(O)_mR^k,
 (43) -C₁₋₆alkyl-S(O)_mR^k,

- (44) $-\text{C}(\text{O})\text{R}^k$,
- (45) $-\text{N}(\text{R}^i)_2$, and
- (46) $-\text{NR}^i\text{R}^k$,

wherein each R^b is unsubstituted or substituted with one to five substituents selected from R^f ,

5

each R^c is independently selected from the group consisting of:

- (1) $-\text{CF}_3$,
- (2) $-\text{CH}_2\text{CF}_3$,
- (3) $-\text{CHF}_2$,
- 10 (4) $-\text{OCHF}_2$,
- (5) $-\text{OCF}_3$,
- (6) CN ,
- (7) oxo ,
- (8) $-\text{OH}$,
- 15 (9) halogen,
- (10) $-\text{C}_1\text{-6alkyl}$,
- (11) $-\text{C}_2\text{-6alkenyl}$,
- (12) $-\text{C}_2\text{-6alkynyl}$,
- (13) $-\text{C}_3\text{-6cycloalkyl}$,
- 20 (14) $-\text{C}_2\text{-6cycloheteroalkyl}$,
- (15) $-\text{C}_1\text{-6alkyl-C}_3\text{-6cycloalkyl}$,
- (16) $-\text{C}_1\text{-6alkyl-C}_2\text{-6cycloheteroalkyl}$,
- (17) $-\text{C}_1\text{-6alkyl-aryl}$,
- (18) $-\text{C}_1\text{-6alkyl-heteroaryl}$,
- 25 (19) $-\text{C}_1\text{-6alkenyl-C}_3\text{-6cycloalkyl}$,
- (20) $-\text{C}_1\text{-6alkenyl-aryl}$,
- (21) $-\text{C}_1\text{-6alkenyl heteroaryl}$,
- (22) $-\text{C}_1\text{-6alkenyl-C}_2\text{-6cycloheteroalkyl}$,
- (23) $-\text{C}_2\text{-6alkynyl-C}_3\text{-6cycloalkyl}$,
- 30 (24) $-\text{C}_2\text{-6alkynyl-C}_2\text{-6cycloheteroalkyl}$,
- (25) $-\text{C}_2\text{-6alkynyl-aryl}$,
- (26) $-\text{C}_2\text{-6alkynyl heteroaryl}$,
- (27) $-\text{OC}_1\text{-6alkyl}$,
- (28) $-\text{OC}_2\text{-6alkenyl}$,
- 35 (29) $-\text{OC}_2\text{-6alkynyl}$,
- (30) $-\text{OC}_3\text{-6cycloalkyl}$,
- (31) $-\text{OC}_2\text{-6heterocycloalkyl}$,

- (32) -O-aryl,
- (33) -O-heteroaryl,
- (34) -OC₁₋₆alkyl-cycloalkyl,
- (35) -OC₁₋₆alkyl-cycloheteroalkyl,
- 5 (36) -OC₁₋₆alkyl-aryl,
- (37) -OC₁₋₆alkyl-heteroaryl,
- (38) -S(O)_mRL,
- (39) -S(O)RL,
- (40) -S-RL,
- 10 (41) -C₁₋₆alkyl-S(O)_mRL,
- (42) -C(O)RL,
- (43) -C(O)C₁₋₆alkyl-RL,
- (44) -OC(O)RL,
- (45) -CO₂RL,
- 15 (46) aryl, and
- (47) heteroaryl,

wherein each R^c is unsubstituted or substituted with one to five substituents selected from R_g;

R^d is independently selected from the group consisting of:

- 20 (1) hydrogen,
- (2) halogen,
- (3) OH,
- (4) oxo,
- (5) -C₁₋₆alkyl,
- 25 (6) -OC₁₋₆alkyl,
- (7) NH₂,
- (8) NH(C₁₋₆alkyl), and
- (9) N(C₁₋₆alkyl)₂;

30 each R^e is independently selected from the group consisting of:

- (1) hydrogen, and
- (2) -C₁₋₆alkyl;

each R^f is selected from the group consisting of:

- 35 (1) halogen, F
- (2) -C₁₋₆alkyl,
- (3) -OH,

- (4) -OC₁₋₆alkyl,
 (5) -OC₃₋₆cycloalkyl,
 (6) -OC₂₋₆cycloheteroalkyl,
 (7) CN,
 5 (8) -NH₂,
 (9) -NH(C₁₋₆alkyl),
 (10) -NH(C₃₋₆cycloalkyl),
 (11) -NH(C₂₋₆cycloheteroalkyl),
 (12) -N(C₁₋₆alkyl)₂,
 10 (13) -N(C₃₋₆cycloalkyl)₂, and
 (14) -N(C₂₋₆cycloheteroalkyl)₂,

wherein each alkyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S(O)₂CH₃;

15 each R_g is selected from the group consisting of:

- (1) halogen,
 (2) C₁₋₆alkyl,
 (3) -OH,
 (4) -OC₁₋₆alkyl,
 20 (5) -S(O)_m-C₁₋₆alkyl,
 (6) -CN,
 (7) -CF₃,
 (8) -OCHF₂, and
 (9) -OCF₃,

25 wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S(O)₂CH₃;

each R^h is independently selected from the group consisting of:

- (1) hydrogen, and
 30 (2) -C₁₋₆alkyl;

each Rⁱ is independently selected from the group consisting of:

- (1) hydrogen, and
 (2) -C₁₋₆alkyl;

35

each R_j is selected from the group consisting of:

- (1) -C₁₋₆alkyl,

- (2) -C₂₋₆alkenyl,
- (3) -C₃₋₆cycloalkyl,
- (4) -C₂₋₆cycloheteroalkyl,
- (5) aryl, and
- 5 (6) heteroaryl,

wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected from: -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, halogen, cyano, and -S(O)₂CH₃;

10 each R^k is selected from the group consisting of:

- (1) -C₁₋₆alkyl,
- (2) -C₂₋₆alkenyl,
- (3) -C₃₋₆cycloalkyl,
- (4) -C₃₋₆cycloalkyl,
- 15 (5) -C₂₋₆cycloheteroalkyl,
- (6) aryl, and
- (7) heteroaryl,

wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected from: -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, halogen, cyano, and -S(O)₂CH₃;

20 each R^L is selected from the group consisting of:

- (1) -C₁₋₆alkyl,
- (2) -C₂₋₆alkenyl,
- 25 (3) -C₃₋₆cycloalkyl,
- (4) -C₂₋₆cycloheteroalkyl,
- (5) aryl, and
- (6) heteroaryl,

wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected from: -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, halogen, cyano, and -S(O)₂CH₃;

each R^m is independently selected from the group consisting of:

- (1) hydrogen, and
- 35 (2) -C₁₋₆alkyl;

- each n is independently 0, 1, 2, 3 or 4;
each m is independently 0, 1 or 2;
each p is independently 0, 1, 2, 3 or 4;
each q is independently 0 or 1; and
5 each r is independently 0 or 1.

2. The compound according to Claim 1 wherein R² is hydrogen; or a pharmaceutically acceptable salt thereof.

- 10 3. The compound according to Claim 1 wherein A is heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to four substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

- 15 4. The compound according to Claim 1 wherein A is selected from the group consisting of:

- (1) pyridine,
(2) pyrimidine,
(3) pyrazine,
(4) indazole,
20 (5) imidazo[1,2-a]pyridine,
(6) pyrrolo[3,2-c]pyridine,
(7) pyrrolo[2,3-b]pyridine,
(8) pyrazole,
(9) thiophene, and
25 (10) 1,2,4-oxadiazole,

wherein A is unsubstituted or substituted with one to four substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

- 30 5. The compound according to Claim 1 wherein A is pyridine, wherein pyridine is unsubstituted or substituted with one to three substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

6. The compound according to Claim 1 wherein B is selected from the group consisting of:

- 35 (1) pyrazine,
(2) pyridine,
(3) pyrimidine, and

(4) pyridazine,

wherein each B is unsubstituted or substituted with one to three substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

5 7. The compound according to Claim 1 wherein B is selected from the group consisting of:

- (1) pyridine,
- (2) pyrimidine, and
- (3) pyridazine,

10 wherein each B is unsubstituted or substituted with one to three substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

8. The compound according to Claim 1 wherein B is pyridine, wherein pyridine is unsubstituted or substituted with one to three substituents selected from R^b; or a
15 pharmaceutically acceptable salt thereof.

9. The compound according to Claim 1 wherein R¹ is selected from the group consisting of:

- (1) -SO₂NH₂,
- 20 (2) -SO₂C₁₋₆alkyl,
- (3) -SO₂NH-C₁₋₆alkyl,
- (4) -SO₂C₃₋₆cycloalkyl,
- (5) -C(O)NH₂,
- (6) -CO₂H,
- 25 (7) -CN,
- (8) halogen,
- (9) -OH,
- (10) -OC₁₋₆alkyl,
- (11) -C₁₋₆alkyl, and
- 30 (12) -CF₃,

wherein each alkyl, and cycloalkyl is unsubstituted or substituted with one to three substituents selected from R^d; or a pharmaceutically acceptable salt thereof.

10. The compound according to Claim 1 wherein R¹ is selected from the group
35 consisting of:

- (1) -SO₂NH₂,
- (2) -C(O)NH₂, and

(3) -OH;

or a pharmaceutically acceptable salt thereof.

11. The compound according to Claim 1 wherein R^3 is selected from the group consisting of: a monocyclic, bicyclic or spirocyclic C_{3-8} cycloalkyl ring, and a monocyclic, bicyclic or spirocyclic C_{2-12} cycloheteroalkyl ring, wherein the cycloheteroalkyl contains 1-4 heteroatoms independently selected from $N(R^m)_r$, O, and S, and wherein each cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to eight substituents selected from R^c ; or a pharmaceutically acceptable salt thereof.

10

12. The compound according to Claim 1 wherein R^3 is a monocyclic, bicyclic or spirocyclic C_{2-12} cycloheteroalkyl ring, wherein the cycloheteroalkyl contains a nitrogen and 0-3 heteroatoms independently selected from $N(R^m)_r$, O, and S, and wherein each cycloheteroalkyl is unsubstituted or substituted with one to eight substituents selected from R^c ; or a pharmaceutically acceptable salt thereof.

15

13. The compound according to Claim 1 wherein R^3 is selected from the group consisting of:

- (1) cyclohexane,
- 20 (2) cycloheptane,
- (3) pyrrolidine,
- (4) azetidine,
- (5) piperidine,
- (6) piperazine,
- 25 (7) azepane,
- (8) morpholine,
- (9) thiomorpholine,
- (10) oxazepane,
- (11) isoindoline,
- 30 (12) dihydroisoquinoline,
- (13) azabicyclo[2.2.1]heptane,
- (14) azabicyclo[3.1.1]heptane,
- (15) azabicyclo[4.1.0]heptane,
- (16) azabicyclo[3.2.1]octane,
- 35 (17) azabicyclo[3.2.0]heptane,
- (18) azaspiro[2.5]octane,
- (19) dihydrothieno[3,2-c]pyridine,

(20) dihydroimidazo[1,2-a]pyrazine, and

(21) hexahydrofuro[3,2-b]pyrrole,

wherein R³ is unsubstituted or substituted with one to eight substituents selected from R^c; or a pharmaceutically acceptable salt thereof.

5

14. The compound according to Claim 1 wherein R³ is selected from the group consisting of:

(1) pyrrolidine,

(2) azetidine,

10 (3) piperidine,

(4) piperazine,

(5) azepane,

(6) morpholine,

(7) thiomorpholine,

15 (8) oxazepane,

(9) isoindoline,

(10) dihydroisoquinoline,

(11) azabicyclo[2.2.1]heptane,

(12) azabicyclo[3.1.1]heptane,

20 (13) azabicyclo[4.1.0]heptane,

(14) azabicyclo[3.2.1]octane,

(15) azabicyclo[3.2.0]heptane,

(16) azaspiro[2.5]octane,

(17) dihydrothieno[3,2-c]pyridine,

25 (18) dihydroimidazo[1,2-a]pyrazine, and

(19) hexahydrofuro[3,2-b]pyrrole,

wherein R³ is unsubstituted or substituted with one to eight substituents selected from R^c; or a pharmaceutically acceptable salt thereof.

30 15. The compound according to Claim 1 wherein R³ is selected from the group consisting of:

(1) piperidine,

(2) azepane, and

(3) morpholine,

35 wherein R³ is unsubstituted or substituted with one to six substituents selected from R^c; or a pharmaceutically acceptable salt thereof.

16. The compound according to Claim 1 wherein

A is selected from the group consisting of:

- (1) pyridine,
- 5 (2) pyrimidine,
- (3) pyrazine,
- (4) indazole,
- (5) imidazo[1,2-a]pyridine,
- (6) pyrrolo[3,2-c]pyridine,
- 10 (7) pyrrolo[2,3-b]pyridine,
- (8) pyrazole,
- (9) thiophene, and
- (10) 1,2,4-oxadiazole,

wherein A is unsubstituted or substituted with one to four substituents selected from R^a;

15

B is selected from the group consisting of:

- (1) pyridine,
- (2) pyrimidine, and
- (3) pyridazine,

20 wherein each B is unsubstituted or substituted with one to four substituents selected from R^b;

R¹ is selected from the group consisting of:

- (1) -SO₃H,
- (2) -SO₂NH₂,
- 25 (3) -SO₂C₁₋₆alkyl,
- (4) -SO₂NH-C₁₋₆alkyl,
- (5) -SO₂C₃₋₆cycloalkyl,
- (6) -C(O)NH₂,
- (7) -CO₂H,
- 30 (8) -CN,
- (9) halogen,
- (10) -OH,
- (11) -OC₁₋₆alkyl,
- (12) -C₁₋₆alkyl, and
- 35 (13) -CF₃,

wherein each alkyl, and cycloalkyl is unsubstituted or substituted with one to three substituents selected from R^d;

R² is hydrogen;

R³ is selected from the group consisting of:

- (1) pyrrolidine,
- 5 (2) azetidine,
- (3) piperidine,
- (4) piperazine,
- (5) azepane,
- (6) morpholine,
- 10 (7) thiomorpholine,
- (8) oxazepane,
- (9) isoindoline,
- (10) dihydroisoquinoline,
- 15 (11) azabicyclo[2.2.1]heptane,
- (12) azabicyclo[3.1.1]heptane,
- (13) azabicyclo[4.1.0]heptane,
- (14) azabicyclo[3.2.1]octane,
- (15) azabicyclo[3.2.0]heptane,
- (16) azaspiro[2.5]octane,
- 20 (17) dihydrothieno[3,2-c]pyridine,
- (18) dihydroimidazo[1,2-a]pyrazine, and
- (19) hexahydrofuro[3,2-b]pyrrole,

wherein R³ is unsubstituted or substituted with one to eight substituents selected from R^c; or a pharmaceutically acceptable salt thereof.

25

17. The compound according to Claim 1 wherein

A is pyridine, wherein pyridine is unsubstituted or substituted with one to three substituents selected from R^a;

30 B is pyridine, wherein pyridine is unsubstituted or substituted with one to three substituents selected from R^b;

R¹ is selected from the group consisting of:

- (1) -SO₂NH₂,
- (2) -C(O)NH₂, and
- 35 (3) -OH;

R² is hydrogen;

R³ is selected from the group consisting of:

- (1) piperidine,
- (2) azepane, and
- (3) morpholine,

wherein R³ is unsubstituted or substituted with one to six substituents selected from R^C;

5 or a pharmaceutically acceptable salt thereof.

18. The compound according to Claim 1 selected from:

- 1) 2-(4,4-difluoropiperidin-1-yl)-N-(6-sulfamoylpyrazin-2-yl)-5-(trifluoromethyl)-nicotinamide;
- 10 2) 2-(4,4-difluoropiperidin-1-yl)-N-(4-hydroxypyrimidin-2-yl)-5-(trifluoromethyl)-nicotinamide;
- 3) 5-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)picolinic acid;
- 4) 4-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)picolinic acid;
- 5) N-(6-cyanopyridin-3-yl)-2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamide;
- 15 6) 2-(azepan-1-yl)-N-(5-(methylsulfonyl)pyridin-3-yl)-5-(trifluoromethyl)nicotinamide;
- 7) 2-(3-(hydroxymethyl)piperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 8) 2-(azepan-1-yl)-N-(5-carbamoylpyridin-3-yl)-5-(trifluoromethyl)nicotinamide;
- 9) 2-(4,4-difluoro-1-piperidyl)-6-methyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 20 10) 5-chloro-2-(4,4-difluoro-1-piperidyl)-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 11) 6-chloro-2-(4,4-difluoropiperidin-1-yl)-4-methyl-N-(5-sulfamoylpyridin-3-yl)nicotinamide;
- 12) 5,6-dicyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 25 13) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 14) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 15) 5-cyclobutyl-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 30 16) 5-(cyclopropylethynyl)-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 17) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 18) 6-(cyclopropylmethyl)-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 35 19) 2-(4,4-difluoroazepan-1-yl)-5,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;

- 20) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide;
- 21) 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 5 22) 6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 23) 5-chloro-6-cyclobutyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 24) 6-cyclobutyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 25) 2-(5,5-Difluoro-2-oxoazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-
10 nicotinamide;
- 26) 2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 27) 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)-nicotinamide;
- 28) 2-(5,5-Difluoro-2-oxoazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-
15 nicotinamide;
- 29) 2-(4,4-Dichloropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 30) 2-(4,4-difluoroazepan-1-yl)-N-[1-(methylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 20 31) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl-N-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridine-3-carboxamide;
- 32) 5-chloro-2-(4,4-difluoroazepan-1-yl)-4,6-dimethyl-N-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridine-3-carboxamide;
- 33) N-{1-[(2-aminoethyl)sulfonyl]-1H-pyrazol-4-yl}-5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methylpyridine-3-carboxamide;
- 25 34) 2-(4,4-difluoroazepan-1-yl)-N-[1-(methylsulfonyl)-1H-indazol-3-yl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 35) 2-(4,4-difluoroazepan-1-yl)-N-[1-(methylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 30 36) N-[1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl]-2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 37) N-[5-cyclopropyl-1-(methylsulfonyl)-1H-pyrazol-4-yl]-2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 38) 2-cyclopropyl-4-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)pyrimidine-5-carboxamide;
- 35 39) 6-cyclopropyl-3-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)pyridazine-4-carboxamide;

- 40) 6-methyl-N-(2-sulfamoylpyridin-4-yl)-2-(3,4,4-trifluoroazepan-1-yl)nicotinamide;
- 41) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methoxy-N-(2-sulfamoylpyridin-4-yl)pyridine-3-carboxamide;
- 42) N-[2-(tert-butylsulfamoyl)pyridin-4-yl]-5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methoxy-
5 pyridine-3-carboxamide;
- 43) 5-cyano-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)-nicotinamide;
- 44) 5-(cyclopropylethynyl)-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;
- 10 45) 2-(azepan-1-yl)-N-(3-cyano-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 46) 5-(cyclopropylmethyl)-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 47) (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 15 48) (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 49) (R)-2-(4,4-dichloro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 20 50) (S)-2-(4,4-dichloro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 51) 2-(4,4-Dichloroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 52) 2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 25 53) 5-chloro-2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]-6-methyl-N-(2-sulfamoyl-4-pyridyl)pyridine-3-carboxamide;
- 54) (S)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 30 55) (R)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 56) (S)-2-(3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 57) (R)-2-(3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 35 58) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[(1S,5S)-1-(trifluoromethyl)-3-azabicyclo[3.2.0]heptan-3-yl]pyridine-3-carboxamide;

- 59) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[(1R,5R)-1-(trifluoromethyl)-3-azabicyclo[3.2.0]heptan-3-yl]pyridine-3-carboxamide;
- 60) N-(2-sulfamoylpyridin-4-yl)-2-((1R,5S)-6,6,7,7-tetrafluoro-3-azabicyclo[3.2.0]heptan-3-yl)-5-(trifluoromethyl)nicotinamide;
- 5 61) 2-[(1S,6S)-7,7-difluoro-6-methyl-3-azabicyclo[4.1.0]heptan-3-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 62) 2-[(1R,6R)-7,7-difluoro-6-methyl-3-azabicyclo[4.1.0]heptan-3-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 63) 2-((1R,5S)-8,8-difluoro-3-oxaoctan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-
- 10 (trifluoromethyl)nicotinamide;
- 64) 2-((1R,5S)-6,6-difluoro-3-azabicyclo[3.2.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 65) 2-((1S,5R)-6,6-difluoro-3-azabicyclo[3.2.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 15 66) (R)-2-(1,1-difluoro-5-azaspiro[2.5]octan-5-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 67) (S)-2-(1,1-difluoro-5-azaspiro[2.5]octan-5-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 68) 2-((1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-
- 20 (trifluoromethyl)nicotinamide;
- 69) 2-((1S,6S)-7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 70) 2-((1R,6R)-7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 25 71) 2-[(1R,4R)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 72) 2-[(1S,4S)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 73) (R)-2-(4,4-difluoro-2-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-
- 30 (trifluoromethyl)nicotinamide;
- 74) (S)-2-(4,4-difluoro-2-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 75) 2-((3R,4s,5S)-4-hydroxy-3,4,5-trimethylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 35 76) 2-((1R,5S)-6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;

- 77) 2-[(3S,4S)-4-hydroxy-3-methyl-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 78) 2-[(3S,4r,5R)-4-hydroxy-3,5-dimethyl-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 5 79) 2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 80) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-(trifluoromethyl)-1-piperidyl]pyridine-3-carboxamide;
- 81) 2-[3-(3,5-difluorophenyl)-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 10 82) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[4-(trifluoromethyl)-1-piperidyl]pyridine-3-carboxamide;
- 83) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-[[4-(trifluoromethyl)phenyl]methyl]-1-piperidyl]pyridine-3-carboxamide;
- 15 84) N-(2-sulfamoyl-4-pyridyl)-2-thiomorpholino-5-(trifluoromethyl)pyridine-3-carboxamide;
- 85) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyridine-3-carboxamide;
- 86) 2-(3-benzyl-6,8-dihydro-5H-imidazo[1,2-a]pyrazin-7-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 20 87) 2-[3,3-dimethyl-4-(2,2,2-trifluoroethyl)piperazin-1-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 88) 2-(2,2-dimethylmorpholin-4-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 89) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[8-(trifluoromethyl)-3,4-dihydro-1H-isoquinolin-2-yl]pyridine-3-carboxamide;
- 25 90) N-(2-sulfamoyl-4-pyridyl)-2-[4-(trifluoromethoxy)isoindolin-2-yl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 91) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[2-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyridine-3-carboxamide;
- 30 92) N-(2-sulfamoyl-4-pyridyl)-2-(3,3,4,4-tetrafluoropyrrolidin-1-yl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 93) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-(trifluoromethyl)azetidin-1-yl]pyridine-3-carboxamide;
- 94) 2-(3-pyrazol-1-ylpyrrolidin-1-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 35 95) 2-[2-(4-fluorophenyl)-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;

- 96) 2-(2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrol-4-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 97) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-[4-(trifluoromethyl)phenoxy]azetidin-1-yl]pyridine-3-carboxamide;
- 5 98) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[4-[3-(trifluoromethyl)phenoxy]-1-piperidyl]pyridine-3-carboxamide;
- 99) 2-[4-(cyclopropylmethyl)-3-oxo-piperazin-1-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 100) N-(2-sulfamoyl-4-pyridyl)-2-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 10 101) 5-chloro-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoyl-4-pyridyl)pyridine-3-carboxamide;
- 102) 2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 103) 2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 15 104) (S)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(2-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 105) (R)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(2-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 20 106) 2-[(2R)-6,6-dimethyl-2-(trifluoromethyl)-1,4-oxazepan-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 107) 2-(2,2-dimethyl-1,4-oxazepan-4-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 108) 2-[(7S)-7-methyl-1,4-oxazepan-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 25 109) N-[2-(tert-butylsulfamoyl)-4-pyridyl]-5-chloro-2-(4,4-difluoroazepan-1-yl)pyridine-3-carboxamide;
- 110) 2-[(2S)-2-methylmorpholin-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 30 111) 2-[(2R)-2-methyl-1,4-oxazepan-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 112) 2-(3-hydroxy-3-methyl-1-piperidyl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 113) 2-(6-fluoro-1,1-dimethyl-isoindolin-2-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 35 114) 2-(azepan-1-yl)-N-(2-methyl-5-sulfamoylthiophen-3-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;

- 115) 2-(4,4-difluoro-5-methylazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 116) 5-chloro-2-[(7R)-7-(difluoromethyl)-1,4-oxazepan-4-yl]-6-methyl-N-(2-sulfamoylpyridin-4-yl)pyridine-3-carboxamide;
- 5 117) 5-chloro-2-[(7S)-7-(difluoromethyl)-1,4-oxazepan-4-yl]-6-methyl-N-(2-sulfamoylpyridin-4-yl)pyridine-3-carboxamide;
- 118) (R)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(7-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 119) (S)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(7-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 10 120) 2-[(2S,7R)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl]-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 121) 2-((2R,7S)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 15 122) 2-((2R,7R)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 123) 2-((2S,7S)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 124) (S)-5-chloro-2-(2-(difluoromethyl)morpholino)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 20 125) (R)-5-chloro-2-(2-(difluoromethyl)morpholino)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 126) N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]pyridine-3-carboxamide;
- 25 127) (R)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(2-(trifluoromethyl)pyrrolidin-1-yl)nicotinamide;
- 128) N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-[3-(trifluoromethyl)pyrrolidin-1-yl]pyridine-3-carboxamide;
- 129) (S)-2-(3-cyanopyrrolidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 30 130) (R)-2-(3-cyanopyrrolidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 131) 2-(4,4-difluoro-3-methylazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 35 132) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;

- 133) 2-((2R,6S)-2-ethyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 134) 2-((2S,6R)-2-ethyl-6-(trifluoromethyl)-morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 5 135) (R)-2-(2,2-dimethyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 136) (S)-2-(2,2-dimethyl-6-(trifluoromethyl)-morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 137) 4-(2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)nicotinamido)picolinamide;
- 10 138) 6-chloro-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoyl-4-pyridyl)pyridine-3-carboxamide;
- 139) 2-(azepan-1-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 140) 2-(azepan-1-yl)-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 141) 2-(azepan-1-yl)-N-(6-sulfamoyl-2-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 15 142) 2-(4,4-difluoroazepan-1-yl)-6-methoxy-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 143) N-(2-methoxypyridin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)-5-(trifluoromethyl)nicotinamide;
- 144) 2-(4,4-difluoroazepan-1-yl)-N-(5-sulfamoyl-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 20 145) 2-(azepan-1-yl)-N-(5-sulfamoyl-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 146) 2-(4,4-difluoroazepan-1-yl)-N-(2-methoxy-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 147) 2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-(methylsulfonyl)pyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 25 148) 2-[(3R)-4,4-difluoro-3-methyl-1-piperidyl]-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 149) 2-[(3S)-4,4-difluoro-3-methyl-1-piperidyl]-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 150) N-(2-cyano-4-pyridyl)-2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 30 151) N-(2-methylsulfonyl-4-pyridyl)-2-[(1R,5S)-6,6,7,7-tetrafluoro-3-azabicyclo[3.2.0]heptan-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 152) 2-[(1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl]-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 35 153) 2-[(1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl]-N-(2-cyano-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;

- 154) (R)-N-(2-cyanopyridin-4-yl)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-5-(trifluoromethyl)-
nicotinamide;
- 155) (S)-N-(2-cyanopyridin-4-yl)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-5-(trifluoromethyl)-
nicotinamide;
- 5 156) 4-(2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)-
picolinamide;
- 157) N-(2-carbamoyl-4-pyridyl)-2-[(3S)-4,4-difluoro-3-methyl-1-piperidyl]-5-
(trifluoromethyl)-pyridine-3-carboxamide;
- 158) N-(2-carbamoyl-4-pyridyl)-2-[(3R)-4,4-difluoro-3-methyl-1-piperidyl]-5-
10 (trifluoromethyl)-pyridine-3-carboxamide;
- 159) 2-(4,4-difluoropiperidin-1-yl)-4-methoxy-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 160) 5-chloro-6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-
sulfamoylpyridin-4-yl)nicotinamide;
- 161) 5-chloro-6-cyclobutyl-2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-
15 sulfamoylpyridin-4-yl)nicotinamide;
- 162) (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoro-
methyl)nicotinamide;
- 163) (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoro-
methyl)nicotinamide;
- 20 164) (S)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-
(trifluoromethyl)nicotinamide;
- 165) (R)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-
(trifluoromethyl)nicotinamide;
- 166) 6-cyclobutyl-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-
25 sulfamoylpyridin-4-yl)nicotinamide;
- 167) 6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-
sulfamoylpyridin-4-yl)nicotinamide;
- 168) 6-cyclobutyl-2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-
sulfamoylpyridin-4-yl)nicotinamide;
- 30 169) 5-chloro-6-cyclobutyl-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-
sulfamoylpyridin-4-yl)nicotinamide;
- 170) 6-chloro-2-(4,4-difluoropiperidin-1-yl)-4-methyl-N-(2-sulfamoylpyridin-4-
yl)nicotinamide;
- 171) 2-(4,4-difluoroazepan-1-yl)-5-(difluoromethoxy)-N-(2-sulfamoylpyridin-4-
35 yl)nicotinamide;
- 172) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;

- 173) 4-(4,4-difluoroazepan-1-yl)-2-methyl-N-(2-sulfamoylpyridin-4-yl)pyrimidine-5-carboxamide;
- 174) 2-(4,4-difluoroazepan-1-yl)-6-(difluoromethyl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 5 175) 2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 176) 4-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)pyridine-2-sulfonic acid;
- 177) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethoxy)nicotinamide
- 10 178) 2-(4,4-difluoropiperidin-1-yl)-5-fluoro-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 179) 3-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide;
- 15 180) 5-(tert-butyl)-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 181) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)-nicotinamide;
- 182) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethoxy)-nicotinamide;
- 20 183) 2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-5-(2,2,2-trifluoroethoxy)-nicotinamide;
- 184) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 25 185) 6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 186) 2-(azepan-1-yl)-N-(5-fluoropyridin-3-yl)-5-(trifluoromethyl)nicotinamide;
- 187) 2-(azepan-1-yl)-5-chloro-N-(2-methoxy-4-pyridyl)-4,6-dimethyl-pyridine-3-carboxamide;
- 30 188) 2-(azepan-1-yl)-5-chloro-4,6-dimethyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 189) 5-chloro-2-(4,4-difluoro-1-piperidyl)-4,6-dimethyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 190) 2-(6-azaspiro[2.5]octan-6-yl)-5-chloro-4,6-dimethyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 35 191) 5-chloro-4,6-dimethyl-2-(1-piperidyl)-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;

- 192) 2-(4,4-difluoroazepan-1-yl)-6-methoxy-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 193) 2-(azepan-1-yl)-N-(5-cyano-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 194) 2-(azepan-1-yl)-N-(5-methoxy-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 5
- 195) 2-(azepan-1-yl)-N-(5-methyl-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 196) 2-(azepan-1-yl)-N-[5-(hydroxymethyl)-3-pyridyl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 197) 2-(azepan-1-yl)-N-(2-cyano-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 10 198) 2-(azepan-1-yl)-N-(2-ethylsulfonyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 199) 2-(azepan-1-yl)-N-(3-bromoimidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 200) 2-(azepan-1-yl)-5-(trifluoromethyl)-N-[5-(trifluoromethyl)-3-pyridyl]pyridine-3-carboxamide;
- 15 201) 2-(azepan-1-yl)-5-chloro-4,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 202) 5-chloro-4,6-dimethyl-2-(6-azaspiro[2.5]octan-6-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 203) 4-(2-(azepan-1-yl)-5-(trifluoromethyl)nicotinamido)picolinamide;
- 20 204) 5-bromo-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 205) 2-(4,4-difluoropiperidin-1-yl)-5-phenyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 206) 2-(4,4-difluoropiperidin-1-yl)-5-(piperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 207) 2-(4,4-difluoropiperidin-1-yl)-5-(1H-pyrazol-1-yl)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 25 208) N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)-5-(trifluoromethyl)-nicotinamide;
- 209) 5-chloro-4,6-dimethyl-N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)nicotinamide;
- 30 210) 2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 211) 5-chloro-4,6-dimethyl-N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(piperidin-1-yl)nicotinamide;
- 212) 2-(azepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)nicotinamide; and
- 35 213) 2-(azepan-1-yl)-5-chloro-4,6-dimethyl-N-(2-oxo-1,2-dihydropyridin-4-yl)nicotinamide; or a pharmaceutically acceptable salt thereof.

19. The compound according to Claim 1 selected from:

- 1) 5-chloro-2-(4,4-difluorocyclohexyl)-4,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 2) 5-chloro-2-cycloheptyl-4,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide
- 5 3) 5-chloro-3-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)pyrazine-2-carboxamide;
- 4) 5-chloro-4,6-dimethyl-2-(4-methylcyclohexyl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- and
- 5) 5-chloro-2-(4,4-difluoroazepan-1-yl)-N,4,6-trimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 10 or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. The use of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament useful for the treatment of a disorder, condition, or disease that is responsive to the inhibition of $\text{Na}_v1.8$ channel activity in a mammal in need thereof.

22. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment, prevention or control of a pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.

23. The use of Claim 22 wherein the disorder is a pain disorder.

24. The use of Claim 23 wherein the pain disorder is selected from: acute pain, inflammatory pain, or neuropathic pain.

25. A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for use in therapy.

26. A method of treating or preventing a disorder, condition or disease that is responsive to the inhibition of $\text{Na}_v1.8$ channel activity in a patient in need thereof comprising administration of a therapeutically effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

27. The method of Claim 26 wherein the disorder is selected from: pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.

28. The method of Claim 27 wherein the disorder is a pain disorder.

5

29. The method of Claim 28 wherein the pain disorder is selected from: acute pain, inflammatory pain, or neuropathic pain.